KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.
Video content above is prompted by the following:
- Please summarize the KATHERINE trial design, which studied adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy.
- How did efficacy data compare amongst the treatment arms?
- How did the recent 5-year OS analysis results presented at SABCS 2023 compare between arms?
- Please comment on the 8+ year follow up data, including IDFS data from this analysis.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
